Polymorphism evaluation in generic tablets containing mebendazole by dissolution tests
This study evaluates the incidence of the polymorphic forms of mebendazole (MBZ) in tablets within the Brazilian market by dissolution tests. The indicated dissolution medium by the USP 30 (United States Pharmacopoeia) and a proposed modified medium were duly compared in order to verify whether they...
| Autores: | , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2012 |
| País: | Argentina |
| Institución: | Consejo Nacional de Investigaciones Científicas y Técnicas |
| Repositorio: | CONICET Digital (CONICET) |
| Idioma: | inglés |
| OAI Identifier: | oai:ri.conicet.gov.ar:11336/192720 |
| Acceso en línea: | http://hdl.handle.net/11336/192720 |
| Access Level: | acceso abierto |
| Palabra clave: | MEBENDAZOLE POLYMORPHISM RAMAN SPECTROSCOPY SOLUBILITY X-RAY POWDER DIFFRACTION https://purl.org/becyt/ford/1.4 https://purl.org/becyt/ford/1 |
| Sumario: | This study evaluates the incidence of the polymorphic forms of mebendazole (MBZ) in tablets within the Brazilian market by dissolution tests. The indicated dissolution medium by the USP 30 (United States Pharmacopoeia) and a proposed modified medium were duly compared in order to verify whether they are able to discriminate the polymorph A from polymorph C in commercial tablets. Dissolution assay tests of physical mixtures in raw materials of polymorph A and polymorph C, as well as of nine tablets of MBZ (available in the Brazilian market), were properly performed. For the dissolution tests, the USP 30 medium (I) and a modified medium (II) were used. The modified medium allowed a reproducible and reliable quality control of MBZ polymorphism in commercial tablets. © 2012 Sociedade Brasileira de Química. |
|---|